Last reviewed · How we verify
NCT04410822
Fecal Incontinence Type Assessment Scale
trial testing Clinical tests in Faecal Incontinence in 150 participants. Completed in 30 June 2020.
30 June 2020
Quick facts
| Lead sponsor | Gérard Amarenco |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 December 2019 |
| Primary completion | 30 June 2020 |
| Estimated completion | 30 June 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- Clinical tests
Conditions studied
- Faecal Incontinence — all drugs for Faecal Incontinence →
Sponsor
Gérard Amarenco
Who can join
18 and older, any sex, with Faecal Incontinence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Urge faecal incontinence (FI) and passive FI are the two subgroups of FI described by the International Continence Society. Urge FI is described as "the inability to defer defecation once the urge is perceived for long enough to reach a toilet" and passive FI as "the involuntary leakage of faeces without forewarning". If several validated questionnaires are available for FI, all of these questionnaires were developed to assess FI severity. In literature, there is only a small number of studies that investigated clinical and paraclinical characteristics of the different phenotype of FI. Moreover, there is an heterogenicity in the definitions used for both urge and passive FI among these studies. Lastly, patients with mixed FI were commonly excluded from these studies. It can be established that there is a lack of validate tools to distinguish patients between subgroups of FI. The aim of the present study was to develop and to validate a new tool in order to investigate and classify patients among the different subgroups of FI (active, passive and mixed) defined by Rome IV criteria. A monocentric prospective study was conducted in the Neuro-urology Department of a University Hospital. All consecutive patients presenting in the Department with FI between December 2019 and June 2020 were screened for inclusion in the present study. Criteria of inclusion were an age older than 18 years old and symptoms of FI according to Rome IV criteria. Exclusion criteria were anorectal fistula, active inflammatory bowel disease, anorectal malignant tumor not treated, rectal or hemorrhoidal prolapses and specific inability regarding the questionnaire (i.e. cognitive disorders, inability to read and to understand questions). Phase 1: review of literature and qualitative interviews: To determine the dimensions of the different subgroups of faecal incontinence, a literature review was performed using Pubmed without date limitation until February 2020. The key words used were "active faecal incontinence", "active fecal incontinence", "passive faecal incontinence", "passive fecal incontinence", "urge faecal incontinence", "urge fecal incontinence", "questionnaire", "scale", "score" and "tool". In parallel to this literature review, semi-structured interviews were performed on 20 patients from December 2019 to February 2020. During this phase, a panel expert of 9 neuro-urologists and gastroenterologists was composed. At the term of all interviews, dimensions that were both the most used by patients and the most discriminative among subgroups of FI were included in the questionnaire. Redaction of questions was then performed by the panel expert. Phase 2: feasibility study: The feasibility study was conducted from February to April 2020 on 30 patients. Each patient was asked to rate each version of the 2 questions with a four-point Likert scale (A: very good, B: good, C: difficult, D: very difficult) regarding acceptance and comprehension of the questions. Phase 3: validation study: To investigate the psychometric properties of the questionnaire, a validation study was performed from April to June 2020 on 100 consecutive patients. In order to evaluate the FITAS' test reproducibility, patients were asked to answer a second time the questionnaire by mail with a second evaluation from 7 days to 10 days after the first one. The "intra-class correlation coefficient" (ICC) was used to determine if these evaluations could lead to similar results for each question. An ICC \> 0.70 was necessary to define reproducibility.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04410822
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Clinical tests
Trials testing the same drug.
- NCT06351176 — Impact of Glycemic Control on Skeletal Outcomes in Adults With Type 1 Diabetes · enrolling by invitation
- NCT04064437 — Prevalence of Vertebral Fractures in Patients With Type 1 Diabetes · completed
- NCT04338646 — Is the Severity of Urinary Disorders Related to Falls in People With Multiple Sclerosis · completed
Other recruiting trials for Faecal Incontinence
Currently open trials in the same condition.
- NCT07126327 — Peristeen Light Explorative Clinical Investigation · NA · recruiting
- NCT06143072 — CArE for OAsI Study: Care Pathways and Anorectal Evaluation for OASI Associated Incontinence · recruiting
- NCT06601985 — Exploring the Effect of Colonic J-pouch in Anorectal Preservation Surgery for Ultra-low Rectal Cancer. · active not recruiting
- NCT05245565 — Effects of Modified Precision Functional Sphincter-Preserving Surgery (PPS) on Ultralow Rectal Cancer · recruiting
- NCT04918329 — Functional Digestive Disorders Observatory · recruiting
Other Gérard Amarenco trials
Trials by the same sponsor.
- NCT05013541 — Effect of Bladder Filling on Rectal Contractions During Cystometry · completed
- NCT04409054 — The Guarding Reflex Anal, Study of the Modulation Function of Rectal Distension · completed
- NCT04067453 — External Anal Sphincter Fatigability · completed
- NCT04057222 — Effect of Need to Void on Rectal Sensory Function in Multiple Sclerosis · completed
- NCT04338646 — Is the Severity of Urinary Disorders Related to Falls in People With Multiple Sclerosis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04410822 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gérard Amarenco
- Last refreshed: 4 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04410822.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing